• Chemistry Analysis
  • Separation Center
  • Center of Natural Product
  • Impurity Isolation and Identification
  • Physicochemical Characterization & Others
  • Pharmaceutical Analysis
  • ASMS Screening
  • Biology
  • In vitro Biology
  • Enzymes/Biochemical Assays
  • Ion Channel
  • Cellular Assays
  • GPCR, Transporter and NHR
  • Radioactive Assays
  • Cancer Cell Panel & In Vitro Oncology Assays
  • In Vitro Assays for Diabetes and Other Metabolic Diseases
  • High Throughput Screening
  • High Content Platform
  • Protein Expression and Purification
  • In vivo Pharmacology & PK/PD
  • Cardiovascular Diseases
  • Metabolic Diseases
  • Fibrosis: Lung, Liver, Kidney
  • Central Nervous System & Pain
  • Respiratory: Asthma & COPD
  • IBS/IBD Animal Models
  • Large Animal Disease Models
  • Infectious Disease
  • Antiviral Services
  • Virology Assays Supporting Human Clinical Trials
  • Antibacterial In Vitro Screening and Pharmacology Services
  • HBV Platform
  • Safety and Early Toxicity
  • In Vitro Safety Profiling for Medchem Support
  • In Vitro Tox Assays for Medchem Support
  • Early Stage Safety Assessment
  • Oncology & Immunology
  • CRISPR/Cas9 Gene Editing
  • In Vitro & In Vivo Library Screening
  • In Vivo CRISPR Animal Models and Services
  • Gene Therapy
  • Tumor Models
  • Cell Line-Derived Xenograft (CDX) Tumor Models
  • Patient-Derived Xenograft (PDX) Tumor Models
  • Syngeneic Tumor Models
  • Human Immune Checkpoint Gene KI Mouse Models
  • hPBMC/HSC Humanized Models
  • Immuno-oncology
  • Translational Oncology
  • Biomarker
  • Discovery Biomarker
  • Clinical Biomarker
  • Autoimmune and Inflammatory Animal Models
  • OncoWuXi Database
  • Structure Based Drug Discovery
  • Protein Production
  • X-ray Crystallography
  • CryoEM
  • Biophysical Assays and Screening
  • FBDD - Fragment Screening
  • Biopharmaceutical Assays
  • Crelux
  • HD Biosciences
  • About Us
  • About WuXi RSD
  • RSD Leadership
  • About WuXi AppTec
  • News & Events
  • News
  • Upcoming Events
  • Resource Library
  • Newsletters
  • Latest Sciences
  • Literature Download
  • Contact
  • CN
    High Throughput Screening

    Identifying New Chemical Matter via High Throughput Screening (HTS)

     

    State-of-the-art Equipment for HTS Support

  • Automation system
  • - Tecan
  • - POD and Echo
  • - JANUS
  • - BRAVO
  • - Platemate Plus
  • Plate washers
  • - Elx405 and Elx406
  • - DropArray Washing StationPlate Sealers
  • Readers to support HTS
  • - BD Biosciences Flow Cytometer with HTS mode
  • - Envision (with stacker)
  • - EnSpire2300
  • - FlexStation III
  • - Bioplex 200 Luminex
  • - FLIPR and Hamammatsu
  • - Topcount and Microbeta2
  • - Q-Patch and Ion Works
  • - Acumen and Odyssey (Li-COR)
  •  

    HTS Compound Collection

  • Majority of the collection is semi-exclusive, non-commercially available
  • Selected from >550K compounds based on diversity, properties, PAINS* & Vacca-Reos# structural filters, reviewed by medicinal chemists, and Rule-of-5 Multi Parameter Optimization (MPO)
  • Total 167k compounds were collected and another 50k compounds expansion in progress
  • Arrayed in 384 plate ready for HTS
  • Stocks and powders available in China
  •  

    HTS Collection (166K) - Property Distributions

     

    WuXi HTS Case Study

  • Over 40 HTS successfully completed with WuXi HTS library.
  • Multiple HTS projects have successfully identified hits for further lead identification and optimization.
  • Targets cover divers fields
  • - Epigenetic targets
  • - GPCRs and nuclear receptors
  • - Kinases
  • Example of primary screening QC data
  • - Z’ value of plates in primary screening
  • - IC50 result of reference compound in cherry picking screening
  •  

    Business Contact 

  • North America: Declan Ryan,  declan.ryan@wuxiapptec.com
  • Europe and Israel: Dave Madge,  dave_madge@wuxiapptec.com
  • China: Marcher Xu,  xu_longji@wuxiapptec.com
  • Japan: Yan Zhu,  yan_zhu@wuxiapptec.com
  • Korea: Suk Young Cho,  sycho@wuxiapptec.com